Speranza Therapeutics is a clinical-stage Biotech with a Focus on COVID-19 Vaccine Development
Located at the heart of Frankfurt am Main, Speransa Therapeutics is led by a dedicated and highly-specialized team, with a strong background in biopharmaceutical research, development and manufacturing. The Company is backed by the Boehringer Ingelheim Venture Fund and partners with leading academic institutions such as the University Hospital Tübingen.
Prime-2-CoV_Beta, our lead COVID-19 vaccine candidate, was originally developed at the University of Tübingen, Germany. It is based on a highly attenuated and non-pathogenic live viral vector D1701-VrV derived from an ORF virus isolate. Used for 20 years in biomedical research and veterinary medicine, this vector has highly beneficial characteristics for the development of a COVID-19 vaccine.
Last updated : June 28, 2023